CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has been issued a patent by the Japanese Patent Office (JPO) for the company’s small molecule dual inhibitor of mTORC1/2 and PI3K VS-5584. The granted patent is titled “Pyrimidine Substituted Purine Compounds As Kinase(s) Inhibitors,” and has claims covering the composition of matter for VS-5584 and VS-5584’s ability to inhibit and regulate cellular metabolism, growth, and proliferation. VS-5584 is currently in a Phase 1 dose escalation study in patients with solid tumors and lymphomas.
Help employers find you! Check out all the jobs and post your resume.
